Founded in 2021 and headquartered in Berkeley (CA), Glyphic Biotechnologies exists to fundamentally rewrite the rules of proteomics.
We believe proteome sequencing will be one of the defining technologies of the 21st century. The precision, scalability, and accessibility of Glyphic's Protein Sequencing by Expansion (ProSE™) will enable the development of critical first-in-class therapies, and deeper insights into life itself.